(NBIX) Neurocrine Biosciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NBIX) Neurocrine Biosciences, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Neurocrine Biosciences, Inc. 4P's Marketing Mix Analysis distills the company’s Product, Price, Place, and Promotion strategy into a concise, actionable overview—showing what Neurocrine offers, how it’s priced, where it’s distributed, and how it’s promoted. This page includes a real preview of the analysis; purchase the full version to get the complete ready-to-use report.
Product
INGREZZA for tardive dyskinesia
INGREZZA is Neurocrine Biosciences' primary commercial asset and a once-daily VMAT2 inhibitor for tardive dyskinesia; it anchors the neurology franchise. In 2024, INGREZZA generated $1.94 billion in net product sales, making it the key revenue driver. Its strong clinical profile and broad U.S. payer access support the product's place in the market.
ONGENTYS for Parkinsons disease
ONGENTYS is an oral adjunct to levodopa and DOPA decarboxylase inhibitor therapy, used for patients who need more control of OFF time in Parkinson’s disease; about 10 million people live with Parkinson’s worldwide, and OFF episodes can affect roughly 20% to 30% of treated patients. It strengthens Neurocrine Biosciences, Inc.’s movement-disorder portfolio by adding a once-daily option in a high-need segment. In the mix, it supports premium specialty positioning and expands reach beyond tardive dyskinesia.
ORILISSA for endometriosis pain
ORILISSA is an oral, non-opioid prescription option for moderate to severe endometriosis pain, giving Neurocrine Biosciences, Inc. a second major commercial franchise beyond neurology. It comes in 150 mg once-daily and 200 mg twice-daily doses, with treatment limited to 24 months and 6 months, respectively, because of bone-loss risk. Endometriosis affects about 1 in 10 women of reproductive age, so the market is large and durable.
ORIAHNN for uterine fibroids
ORIAHNN is Neurocrine Biosciences, Inc.’s oral, non-surgical option for premenopausal women with heavy menstrual bleeding from uterine fibroids; fibroids affect up to 77% of women by age 50, so the need is large. Its product value is clear: symptom control without surgery, which helps the endocrine and gynecology franchise. ORIAHNN also fits a premium specialty-drug model, where access and clinician education drive use.
- Oral, non-surgical treatment
- Targets heavy menstrual bleeding
- Addresses a high-prevalence need
- Strengthens women’s health mix
5 pipeline candidates
Neurocrine Biosciences, Inc. lists 5 pipeline candidates: NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. The programs span epilepsy, essential tremor, major depressive disorder, anhedonia, and schizophrenia, showing a broad CNS research base. This 5-asset slate helps support future brand depth beyond the company’s current commercial products.
- 5 named pipeline candidates
- 5 CNS indications covered
- Broadens long-term growth options
INGREZZA Drives Neurocrine’s Revenue, Backed by a Broadening Pipeline
Neurocrine Biosciences, Inc.’s Product mix is led by INGREZZA, which generated $1.94 billion in 2024 net product sales and anchors its CNS franchise. ORILISSA and ORIAHNN extend the lineup into women’s health, while ONGENTYS adds Parkinson’s support. The 5-name pipeline broadens future product depth.
| Brand | Role | Key data |
|---|---|---|
| INGREZZA | Core revenue | $1.94B sales |
| ORILISSA | Women’s health | Endometriosis |
| ORIAHNN | Women’s health | Fibroids |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Neurocrine Biosciences, Inc. covering Product, Price, Place, and Promotion with real-world strategic context.
Editable Excel File
Condenses Neurocrine Biosciences’ 4Ps into a clear, at-a-glance view that quickly relieves planning and presentation pain points.
Reference Sources
Provides a concise, traceable bibliography linking Neurocrine Biosciences claims to primary industry reports, regulatory filings, and peer-reviewed studies for fast, defensible due diligence.
Place
Prescription-only channel
In 2025, Neurocrine Biosciences, Inc. kept its medicines in a prescription-only channel, so patients get them through licensed clinicians and specialty pharmacies, not OTC shelves. That makes physician diagnosis, titration, and follow-up central to access for brands like INGREZZA and CRENESSITY. It also helps Neurocrine control safety and refill use.
Specialty pharmacy fulfillment
Specialty pharmacy fulfillment is central for Neurocrine Biosciences, Inc. because it verifies prescriptions, ships therapies, and coordinates refills for chronic CNS and women’s health treatments. In 2024, Neurocrine Biosciences, Inc. reported $2.36 billion in net product sales, showing how access workflows support revenue. This channel also helps keep refill gaps low for long-term patients.
Specialist prescribers
Neurocrine Biosciences, Inc. relies on specialist prescribers in 4 key fields: neurology, psychiatry, gynecology, and endocrinology. That matters because these doctors treat the exact conditions behind the Company Name’s portfolio, so access depends on office-based detailing and specialist networks, not mass retail shelf space.
San Diego California headquarters
Neurocrine Biosciences was founded in 1992 and keeps its headquarters in San Diego, California, as the company’s main operating base. That site supports commercial work, research, and corporate coordination, which matters in FY2025 when Neurocrine reported continued growth from its San Diego-led U.S. platform and a portfolio centered on brain and endocrine therapies.
- Founded: 1992
- HQ: San Diego, California
- Use: commercial, R&D, corporate
- Role: operational base
8 strategic licensing partners
Neurocrine Biosciences, Inc. works with eight strategic licensing partners: Heptares Therapeutics, Takeda, Idorsia, Xenon, Voyager, BIAL, Mitsubishi Tanabe, and AbbVie. These alliances widen research reach and give Neurocrine access to more development paths, which helps feed its pipeline and speed execution across markets.
The partner base is broad across discovery, licensing, and regional development, so it lowers single-partner dependence and supports later-stage optionality. In a 4P view, this strengthens product access and pipeline depth at the same time.
- 8 licensing partners support pipeline reach
- Broader access to R&D and development
- Helps market and pipeline execution
Neurocrine’s Specialty Rx Strategy Drives Controlled Access and Growth
Neurocrine Biosciences, Inc. uses a specialty, prescription-only place strategy in 2025, so access runs through clinicians and specialty pharmacies rather than retail shelves. That fits chronic CNS and endocrine care and supports refill control. The San Diego base also anchors U.S. commercial and R&D execution.
| Place factor | 2025 data |
|---|---|
| Channel | Rx + specialty pharmacy |
| HQ | San Diego, California |
| Net product sales | $2.36B (2024) |
Preview Before You Purchase
Neurocrine Biosciences, Inc. Reference Sources
The preview shown here is the actual Neurocrine Biosciences 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.
This is the same ready-made, editable Marketing Mix analysis you'll download immediately after checkout, fully complete and ready to use.
Promotion
Specialist sales force
Neurocrine Biosciences, Inc. uses a specialist sales force to reach prescribers who diagnose and monitor complex CNS and endocrine diseases, including neurologists, psychiatrists, gynecologists, and endocrinologists. This fits prescription drugs where treatment starts with diagnosis and then needs ongoing follow-up. In 2024, Neurocrine Biosciences, Inc. reported $2.36 billion in revenue, up 24% year over year, showing the scale of this focused model.
Disease awareness campaigns
Disease awareness campaigns let Neurocrine Biosciences, Inc. educate on tardive dyskinesia, Parkinson’s disease, endometriosis, and uterine fibroids. With about 500,000 U.S. adults living with tardive dyskinesia and endometriosis affecting roughly 190 million women worldwide, earlier symptom recognition can speed diagnosis and treatment. That can lift prescriptions for flagship therapies like INGREZZA and ORILISSA.
Patient support services
Neurocrine Biosciences, Inc. can use patient support services to promote access with copay help, education, and adherence support. This lowers friction after the prescription is written and fits how specialty pharma wins therapy starts. With Neurocrine Biosciences, Inc. annual product sales above $2 billion, even small gains in fill and refill rates can matter.
Scientific congress presence
Scientific congress presence lets Neurocrine Biosciences, Inc. share clinical data at medical meetings, so healthcare professionals and researchers can assess its programs with current evidence. That matters for pipeline credibility and brand trust, especially in CNS, where Ingrezza sales reached $2.2 billion in 2024 and investors watch proof points closely.
- Shares data with HCPs
- Builds pipeline credibility
- Supports brand trust
Investor and corporate communications
Neurocrine Biosciences uses earnings releases, SEC filings, and conference calls to keep investors informed on sales, pipeline progress, and deal milestones. In its latest public updates, management used these channels to reinforce visibility with analysts and institutional holders, while tying operating results to product launches and collaboration execution.
- Quarterly earnings updates
- SEC filings and guidance
- Pipeline and deal progress
- Investor and analyst focus
Neurocrine’s Focused Promotion Powers Strong Specialty Drug Growth
Promotion at Neurocrine Biosciences, Inc. is built on targeted HCP detail, disease-awareness campaigns, patient support, and congress data. This fits specialty drugs for CNS and endocrine care, where diagnosis and follow-up drive starts and refills. In 2024, revenue was $2.36 billion, and INGREZZA sales reached $2.2 billion, showing the payoff of this focused model.
| Channel | Role |
|---|---|
| HCP sales force | Target prescribers |
| Awareness campaigns | Speed diagnosis |
| Patient support | Lift adherence |
Price
Premium branded pricing
Neurocrine Biosciences sells branded specialty therapies, so price is set by clinical value and long-term use, not generic cost pressure. In 2024, the Company generated about $2.3 billion in product sales, led by Ingrezza, which shows the premium, chronic-care model. Patient out-of-pocket cost still depends on insurance design, prior auth, and copay support.
Rebate and formulary contracting
Net price at Neurocrine Biosciences, Inc. is set by payer deals and rebates, so gross sales do not equal cash collected. In specialty pharma, formulary access can move realized revenue per script by double-digit percentages; Neurocrine Biosciences, Inc. said 2025 net product sales stayed above $2 billion, so coverage terms matter a lot.
Copay assistance programs
Neurocrine Biosciences, Inc. offers copay support for eligible patients, which can lower the amount due at the pharmacy counter. Copay cards and savings programs are meant to remove cost friction at start and refill. In drug access studies, lower out-of-pocket costs have been linked to better initiation and refill adherence, often by 10% to 20%.
Prior authorization controls
Prior authorization and step edits are common on specialty drugs, so Neurocrine Biosciences, Inc. must price for both value and access. If approval takes days or weeks, fills slow and net sales can slip even when demand is strong.
That link is real in neuro and rare-disease care, where a single delay can push patients to abandon therapy. The price point must support payer coverage, because tighter controls protect budgets but can raise the cost of access.
- Access controls shape net sales.
- Delays can cut starts.
- Pricing must fit payer rules.
Net sales depend on payer mix
Neurocrine Biosciences, Inc. gets different realized prices by payer mix: commercial plans usually pay closer to list price, while Medicare and Medicaid use tighter rebates and coverage rules, so net sales are lower than gross sales. In FY2025, that spread still mattered most for Ingrezza, where reimbursement terms drive net revenue more than sticker price. A higher Medicaid or Medicare share cuts realized price even if unit volume rises.
- Commercial mix lifts realized price
- Medicare and Medicaid lower net sales
- Rebates make net revenue below list price
Neurocrine’s Pricing Power Stays Premium, Payer-Led
Price at Neurocrine Biosciences, Inc. is premium and payer-led, not volume-led. In FY2025, net product sales stayed above $2 billion, with Ingrezza still driving realized price. Gross-to-net pressure from rebates, prior auth, and copays keeps net price below list.
| FY2025 | Price signal |
|---|---|
| Net product sales | >$2.0B |
| Key driver | Ingrezza |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.